Mucorales Real-time PCR
Test Code: 3200
Cpt Code:87798 (x1)
Real-time PCR detection of Mucorales (also referred to as Zygomycetes) DNA in BAL and tissue samples may aid in diagnosis of invasive fungal infection (IFI) in high risk populations. High risk patients include those with neutropenia, solid organ transplant, hematopoietic stem cell transplant, cancer, diabetes and skin trauma. Difficult to differentiate from other filamentous fungi, mucormycosis has been found to have mortality rates in excess of 50%, depending on patient population and presentation. Further, Mucorales demonstrates limited susceptibility to a variety of antifungal therapies including Voriconazole. Early diagnosis of Mucorales has been associated with improved patient outcomes.
The use of Mucorales PCR in BAL and tissue has shown superior sensitivity over culture samples from animal models of infection and various publications indicate performance in human specimens (e.g. 100% sensitivity in biopsy tissue, 100% sensitivity established in fresh tissue samples that were culture negative, and 100% specificity in control tissue samples). The number of published studies utilizing BAL (15 studies) and biopsy (>1300) are significantly higher than any other specimen type, the next most often cited being upper respiratory specimens (n=3).
Extraction of Mucorales DNA from specimen followed by amplification and detection using qualitative real-time PCR. A full-process internal control is added to each clinical specimen in order to ensure the extraction was performed correctly and the PCR reaction was not inhibited. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
The Mucorales PCR detects the most common causative agents of mucormycosis including 32 strains encompassing eight Mucorales genera. Additionally, no cross reactivity was detected from the most common non-Mucorales fungal pathogens with the exception of high levels of Trichosporon spp.
Causes For Rejection
Specimens that have been stored at ambient temperature, specimens received in trap containers, specimens other than those listed or specimens that have been stored at 2 to 8°C for >2 days. If storage longer than 2 days is needed, specimens should be frozen at -70°C. Unless indicated as stored frozen, the specimen will be rejected if the draw date is >2 days upon receipt to Viracor-IBT Laboratories.
Same day (within 8 to 12 hours of specimen receipt), Monday through Saturday.
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor-IBT test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Viracor-IBT Laboratories, 1001 NW Technology Dr, Lee's Summit, MO 64086.
2 mL collected in a sterile, screw top tube; specimen should be stored at 2 to 8°C or frozen in a non-self-defrosting freezer and shipped with frozen gel packs or dry ice for overnight delivery to Viracor-IBT Laboratories. If storage longer than 2 days is needed, specimens should be frozen at -70° C prior to shipment.
Place fresh tissue in a sterile, screw top container. The preferred handling is to not add water, saline or other fluid media to the tissue container. Store frozen and ship on dry ice for overnight delivery to Viracor-IBT Laboratories. Formalin fixed, paraffin embedded tissue will not be accepted.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor-IBT's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor-IBT assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
PCR tests are performed pursuant to a license agreement with Roche Molecular Systems, Inc.
CDC Web site. http://www.cdc.gov/fungal/mucormycosis/definition.html. Last updated Jan 5, 2012.
Vitale RG, de Hoog GS, Schwarz P, et al. Antifungal susceptibility and phylogeny of opportunistic members of the order Mucorales. J Clin Microbiol. 2012 Jan;50(1);66-75.
Kasai M., Harrington SM, Francesconi A, et al. Detection of a molecular biomarker for Zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol. 2008 Nov;46(11);3690-702.
Dannoui E, Schwarz P, Slany M, et al. Molecular detection and identification of Zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Disease (ESCMID) fungal infection study group (EFISG) evaluation. J Clin Microbiol. 2010 June;48(6):2043-6.
Bernal-Martinzez L, Buitrago MJ, Castelli MV, Rodriquez-Tudela JL and Cuenca-Estrella M. Development of a single tube multiplex PCR to detect the most clinically relevant Mucormycetes species. Clin Microbiol Infect. 2013 Jan;19(1):E1-7.
Hammond SP, Bialek R. Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011 June;49(6):2151-3.
Hata DJ, Buckwalter SP, Pritt BS, Roberts GD, Wengenack NL (2008) Real-time PCR method for detection of zygomycetes .J Clin Microbiol. 2008 Jul;46(7):2353-8.
Data on file at Viracor-IBT.